M
M. T. Camps
Researcher at Spanish National Research Council
Publications - 26
Citations - 2017
M. T. Camps is an academic researcher from Spanish National Research Council. The author has contributed to research in topics: Single-nucleotide polymorphism & Antiphospholipid syndrome. The author has an hindex of 17, co-authored 26 publications receiving 1781 citations.
Papers
More filters
Journal ArticleDOI
Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients
Ricard Cervera,Munther A. Khamashta,Y Shoenfeld,M. T. Camps,Søren Jacobsen,Emese Kiss,Margit Zeher,Angela Tincani,I. Kontopoulou-Griva,Mauro Galeazzi,Francesca Bellisai,Pier Luigi Meroni,R. H. W. M. Derksen,P. G. De Groot,Erika Gromnica-Ihle,Marta Baleva,Marta Mosca,Stefano Bombardieri,Frédéric Houssiau,Jean-Christophe Gris,Isabelle Quéré,Eric Hachulla,Carlos Vasconcelos,B. Roch,Antonio Fernández-Nebro,J.C. Piette,Gerard Espinosa,Silvia Bucciarelli,C. N. Pisoni,Maria Laura Bertolaccini,M. C. Boffa,G. R. V. Hughes +31 more
TL;DR: Patients with APS still develop significant morbidity and mortality despite current treatment, and it is imperative to increase the efforts in determining optimal prognostic markers and therapeutic measures to prevent these complications.
Journal ArticleDOI
Morbidity and mortality in the antiphospholipid syndrome during a 5-year period
Ricard Cervera,Munther A. Khamashta,Y Shoenfeld,M. T. Camps,S Jacobsen,E. Kiss,Margit Zeher,Angela Tincani,I. Kontopoulou-Griva,Mauro Galeazzi,Francesca Bellisai,Pl Meroni,R. H. W. M. Derksen,de Peter Groot,Erika Gromnica-Ihle,Marta Baleva,Marta Mosca,Stefano Bombardieri,F. Houssiau,J-C Gris,Isabelle Quéré,Eric Hachulla,Carlos Vasconcelos,B. Roch,Antonio Fernández-Nebro,J-C Piette,Gerard Espinosa,Silvia Bucciarelli,Cecilia N. Pisoni,Maria Laura Bertolaccini,M C Boffa,G. R. V. Hughes +31 more
TL;DR: Patients with APS still develop significant morbidity and mortality despite current treatment (oral anticoagulants or antiaggregants, or both), according to this 5-year study.
Journal ArticleDOI
Systemic involvement in primary Sjögren’s syndrome evaluated by the EULAR-SS disease activity index: analysis of 921 Spanish patients (GEAS-SS Registry)
Manuel Ramos-Casals,Pilar Brito-Zerón,Roser Solans,M. T. Camps,A. Casanovas,Bernardo Sopeña,Bernardino Díaz-López,Francisco-Javier Rascón,Rami Qanneta,Guadalupe Fraile,Roberto Pérez-Alvarez,J.L. Callejas,M. Ripoll,Blanca Pinilla,M. Akasbi,E. Fonseca,Jesús Canora,María-Elvira Nadal,Gloria de la Red,Inés Fernández-Regal,I. Jiménez-Heredia,J. A. Bosch,María-del-Mar Ayala,Lluisa Morera-Morales,B. Maure,Arantxa Mera,M. Ramentol,Soledad Retamozo,Belchin Kostov +28 more
TL;DR: Primary SS is undeniably a systemic disease, with the joints, lungs, skin and peripheral nerves being the most frequently involved organs and Clinically the ESSDAI provides a reliable picture of systemic involvement in primary SS.
Journal ArticleDOI
The STAT4 gene influences the genetic predisposition to systemic sclerosis phenotype
Blanca Rueda,J. C. A. Broen,C. P. Simeon,Roger Hesselstrand,B. Diaz,H. Suarez,Norberto Ortego-Centeno,Gabriela Riemekasten,V. Fonollosa,Madelon C. Vonk,F.H.J. van den Hoogen,Julio Sánchez-Román,M. A. Aguirre-Zamorano,Rosa Garcia-Portales,A. Pros,M. T. Camps,M. A. Gonzalez-Gay,M. J. H. Coenen,P. Airo,L. Beretta,R. Scorza,J.M. van Laar,María Francisca González-Escribano,J. L. Nelson,Trdj Radstake,Javier Martin +25 more
TL;DR: A strong and reproducible association of the STAT4 gene with the genetic predisposition to lcSSc is shown suggesting that this gene seems to be one of the genetic markers influencing SSc phenotype.
Journal Article
Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases.
Manuel Ramos-Casals,Francisco J. García-Hernández,de Ramón E,José Luis Callejas,Agustin Martinez-Berriotxoa,L Pallarés,Luis Caminal-Montero,Albert Selva-O'Callaghan,J. Oristrell,Carmen Hidalgo,Roberto Pérez-Alvarez,Micó Ml,Medrano F,Gómez de la Torre R,Cándido Díaz-Lagares,M. T. Camps,Norberto Ortego,Julio Sánchez-Román +17 more
TL;DR: Although not yet licensed for this use, rituximab is currently used to treat severe, refractory systemic autoimmune diseases, with the most favourable results being observed in Sjögren's syndrome, inflammatory myopathies, systemic lupus erythematosus and cryoglobulinemia.